



PCT/EP 0 3 / 0 3 4 7 0
10/510027
INVESTOR IN PEOPLE

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

REC'D 14 MAY 2003

WIPO

PCT


The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Stephen Handley

Dated 12 March 2003

Patents Act 1977
(Rule 16)

03 APR 2002

The
Patent
Office

1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP10 8QQ

1. Your reference

4-32435P1

2. 0207729.5

3 APR 2002

3. Full name, address and postcode of the or of each applicant
(underline all surnames)NOVARTIS AG
LICHTSTRASSE 35
4056 BASEL
SWITZERLAND

Patent ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

SWITZERLAND

7125487005

4. Title of invention

Organic compounds

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

B.A. YORKE & CO.
CHARTERED PATENT AGENTS
COOMB HOUSE, 7 ST. JOHN'S ROAD
ISLEWORTH
MIDDLESEX TW7 6NH

Patents ADP number (if you know it)

1800001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)Date of filing
(day/month/year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day/month/year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

Yes

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

(see note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 21

Claim(s) 2

Abstract

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application

Signature

Date

B. A. Yorke & Co

B.A. Yorke & Co.

03 April 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Mrs. E. Cheetham
020 8560 5847

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.


Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Organic Compounds

The present invention relates to indolylmaleimide derivatives, process for their production and pharmaceutical compositions containing them.

More particularly the present invention provides a compound of formula I




wherein

R_a is H, CH₃ or isopropyl,

R_b is H; halogen; CF₃; C₁₋₆alkoxy; C₁₋₆alkyl; or C₃₋₇cycloalkyl, and either

I. R is a radical of formula (a)



(a)


wherein

R₁ is piperazin-1-yl optionally substituted by CH₃ in position 3 or 4,

R₂ is H; CH₃; or CF₃; and

R₃ is Cl; Br; CF₃; or CH₃; or


II. R is a radical of formula (b)



(b)

wherein R₄ is piperazin-1-yl, 3-methyl-piperazin-1-yl or 4,7-diaza-spiro [2,5] oct-7-yl; or

III. R is a residue of formula (c)




wherein

R₁₄ is piperazin-1-yl optionally substituted by CH₃ in position 3 or 4, or 4,7-diaza-spiro [2,5] oct-7-yl;

R₁₅ is H; CH₃; or CF₃; and


R₁₆ is Cl; Br; CF₃; or CH₃; each of R₁₅ and R₁₆ being other than CH₃ when R_b is H; or

IV. R is a radical of formula (d)



wherein R₈ is piperazin-1-yl, 3-methyl-piperazin-1-yl or 4-benzyl-piperazin-1-yl; or

V. R is a radical of formula (e)



wherein R₉ is 4,7-diaza-spiro [2,5] oct-7-yl; or piperazin-1-yl substituted in position 3 by methyl or ethyl.

The compounds of formula I may exist in free form or in salt form, e.g. addition salts with e.g. organic or inorganic acids, for example, hydrochloric acid, acetic acid.


It will be appreciated that the compounds of formula I may exist in the form of optical isomers, racemates or diastereoisomers. For example, a ring carbon atom bearing a substituent in the position 3 of the piperazinyl residue is asymmetric and may have the D- or L- configuration. It is to be understood that the present invention embraces all enantiomers and their mixtures. Similar considerations apply in relation to starting materials exhibiting asymmetric carbon atoms as mentioned.

Alkyl or alkoxy may be straight or branched. Cycloalkyl is preferably C₃₋₆cycloalkyl. Halogen may be F, Cl, Br or I, preferably F, Cl or Br.


R is preferably a radical of formula (a) or (c).

In the radical of formula (a) or (c), each of R₂ or R₁₅ is preferably H or CH₃ and each of R₃ or R₁₆ is preferably Cl or CF₃. R₃ or R₁₆ is preferably in ortho to the free bond. R₂ or R₁₅ is preferably in meta.

The present invention also includes a process for the preparation of a compound of formula I which process comprises reacting a compound of formula II



wherein R_a and R_b are as defined above,
with a compound of formula III



wherein R is as defined above,

and, where required, converting the resulting compound of formula I obtained in free form to a salt form or vice versa, as appropriate.

The process may conveniently be effected in the presence of a strong base, e.g. t-BuOK, e.g. as disclosed in PCT/EPO1/12785.

Compounds of formula II and III may be prepared in accordance with known methods, e.g. as disclosed in PCT/EPO1/12785.


Insofar as the production of the starting materials is not particularly described, the compounds are known or may be prepared analogously to methods known in the art or as described hereafter.

The following examples are illustrative of the invention.

RT	=	room temperature
THF	=	tetrahydrofuran
FCC	=	flash column chromatography
TBAF	=	tetrabutyl ammonium fluoride
BINAP	=	2,2'-bis(diphenylphosphino)-1,1'-binaphthyl

$\text{Pd}_2(\text{dba})_3 = \text{Pd}(0)\text{-bis}(\text{dibenzylidenacetone})$


Example 1: 3-[2-Chloro-3-methyl-5-(4-methyl-piperazin-1-yl)-phenyl]-4-(1*H*-indol-3-yl)-pyrrole-2,5-dione



2-[2-Chloro-3-methyl-5-(4-methyl-piperazin-1-yl)-phenyl]-acetamide (211 mg, 0.75 mmol) and 3-indoleglyoxylate (270 mg, 1.35 mmol) are dissolved in THF (5 mL). A solution of 1.0 M *tert*-BuOK in THF (2.98 mL, 4 eq) is added and the mixture is stirred at 35°C overnight. The reaction is diluted with AcOEt (20 mL) and washed with H₂O (20 mL) and brine (10 mL). The organic phase is dried over Na₂SO₄ and the solvent is evaporated. The residue is purified by FCC (AcOEt/AcOH/H₂O 7:1:1) to afford the title compound in the form of its acetate salt.

¹H NMR (DMSO, 400 MHz) δ 2.16 (s, 3H), 2.31 (s, 3H), 2.32-2.38 (m, 4H), 2.97-3.10 (m, 4H), 6.61 (d, *J* = 8.0 Hz, 1H), 6.71-6.77 (m, 2H), 7.04 (d, *J* = 2.8 Hz, 1H), 7.08 (dd, *J* = 7.4, 7.2 Hz, 1H), 7.41 (d, *J* = 8.2 Hz, 1H), 7.98 (d, *J* = 1.5 Hz, 1H), 11.05 (br s, 1H), 11.90 (br s, 1H); ES-MS: 435 [M+H]⁺.


2-[2-Chloro-3-methyl-5-(4-methyl-piperazin-1-yl)-phenyl]-acetamide



used as starting material may be prepared as follows:

(5-Bromo-2-chloro-3-methyl-phenyl)-acetic acid methyl ester (2.0 g, 7.2 mmol), *N*-methylpiperazine (960 μ L, 8.6 mmol) and Cs₂CO₃ (3.3 g, 10.1 mmol) are suspended in toluene (80 mL). Pd(OAc)₂ (81 mg, 0.36 mmol) and BINAP (224 mg, 0.36 mmol) are added and the reaction is stirred at 100°C overnight. The mixture is filtered through Celite and the solvent is evaporated. The residue is purified by FCC (AcOEt/AcOH/H₂O 60:15:15) to afford 2-[2-chloro-3-methyl-5-(4-methyl-piperazin-1-yl)-phenyl]-acetic acid methyl ester. The ester is suspended in NH₄OH 25% (60 mL). The mixture is stirred overnight at RT and the precipitate is filtered off to yield the amide. ¹H NMR (DMSO, 400 MHz) δ 2.20 (s, 3H), 2.27

(s, 3H), 2.40-2.45 (m, 4H), 3.07-3.13 (m, 4H), 3.48 (s, 2H), 6.78 (s, 1H), 6.82 (s, 1H), 6.91 (br s, 1H), 7.34 (br s, 1H).



CuCl₂ (8.0 g, 0.06 mol) and tert-butylnitrile (8.9 mL, 0.074 mol) are suspended in acetonitrile (60 mL). 1,1-dichloroethylene is added dropwise at 20°C. 5-Bromo-2-chloro-3-methyl-phenylamine (11.0 g, 0.05 mol), dissolved in acetonitrile (60 mL), is added and the reaction is stirred at RT for 3 h. The mixture is poured into aqueous 20% HCl (150 mL) and the aqueous phase is extracted with CH₂Cl₂ (2 x 150 mL). The organic phase is dried over Na₂SO₄ and the solvent is evaporated. The residue is purified by FCC (hexane/CH₂Cl₂ 9:1) to afford 5-bromo-2-chloro-1-methyl-3-(2,2,2-trichloro-ethyl)-benzene. The intermediate is redissolved in MeOH (80 mL) and heated to 70°C. A solution of 5.4 M NaOMe in MeOH (28.4 mL) is added dropwise and the reaction is stirred at 70°C for 3 h. The reaction is cooled to RT and concentrated H₂SO₄ (10 mL) is added. The reaction is stirred at reflux for 1 h. The mixture is diluted with H₂O (200 mL) and extracted with CH₂Cl₂ (2 x 200 mL). The combined organic phases are dried over Na₂SO₄ and the solvent is evaporated. The residue is purified by FCC (hexane/CH₂Cl₂ 9:1 to 1:1) to afford (5-bromo-2-chloro-3-methyl-phenyl)-acetic acid methyl ester. ¹H NMR (CDCl₃, 400 MHz) δ 2.26 (s, 3H), 3.61 (s, 3H), 3.63 (s, 2H), 7.15 (s, 1H), 7.21 (s, 1H).


By following the procedure of Example 1 but using the appropriate starting materials, the compounds of formula I wherein R is a residue of formula (a), as indicated in Table 1 below may be obtained.

TABLE 1

Example	R ₁	R ₂	R ₃	R _a	M.S. Data
2	-(4-methyl-piperazin-1-yl)	3-CH ₃	2-CH ₃	CH ₃	MH ⁺ 429
3	-(4-methyl-piperazin-1-yl)	3-CH ₃	2-CH ₃	H	MH ⁺ 415
4	-(4-methyl-piperazin-1-yl)	3-CH ₃	2-Cl	CH ₃	MH ⁺ 449
5	1-piperazinyl	3-CH ₃	2-Cl	H	MH ⁺ 421
6	1-piperazinyl	3-CH ₃	2-Cl	CH ₃	MH ⁺ 435
7	3- <i>R</i> -methyl-piperazin-1-yl	3-CH ₃	2-Cl	CH ₃	MH ⁺ 449
8	3- <i>R</i> -methyl-piperazin-1-yl	3-CH ₃	2-Cl	H	MH ⁺ 435

9	1-piperazinyl	3-CF ₃	2-Cl	CH ₃	MH ⁺ 503
10	1-piperazinyl	3-CF ₃	2-Cl	H	MH ⁺ 489


Example 11: 3-[3-(4,7-Diaza-spiro[2.5]oct-7-yl)-naphthalen-1-yl]-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione



2-[3-(4,7-Diaza-spiro[2.5]oct-7-yl)-naphthalen-1-yl]-acetamide (100 mg, 0.30 mmol) and (1-methyl-1H-indol-3-yl)-oxo-acetic acid methyl ester (97 mg, 0.44 mmol) are azeotroped three times with dry THF and then dissolved in dry THF (3 ml). A solution of 1.0 M KOtBu in THF (1.2 ml) is added dropwise over 20 minutes at RT. After 5 minutes, TLC analysis indicates complete conversion of starting materials. The reaction is quenched by the addition of water (5 ml). The mixture is diluted with EtOAc and washed twice with saturated aq. NH₄Cl. The aqueous layers are back extracted twice with EtOAc. The combined organic layers are dried over Na₂SO₄ and the solvent is evaporated. The residue is purified by FCC

(EtOAc/AcOH/H₂O 800:55:45) to afford the title compound as its acetate salt. The compound is dissolved in MeOH/TFA and the solvent is removed to yield the title compound as its trifluoroacetate salt. ¹H NMR (DMSO, 400 MHz) δ 0.95 (m, 4H), 3.39 (br, 4H), 3.49 (br, 2H); 3.86 (s, 3H), 6.16 (d, J = 7.9 Hz, 1H), 6.46 (dd, J = 6.6 / 7.9 Hz, 1H), 7.00 (dd, J = 6.6 / 7.9 Hz, 1H), 7.13 (dd, J = 7.6 / 7.6 Hz, 1H), 7.40 (m, 4H), 7.55 (d, J = 8.5 Hz, 1H), 7.78 (d, J = 7.6 Hz, 1H), 8.14 (s, 1H), 9.10 (br, 2H), 11.17 (s, 1H); ES-MS: 463 [M+H]⁺.

2-[3-(4,7-Diaza-spiro[2.5]oct-7-yl)-naphthalen-1-yl]-acetamide, used as starting material may be prepared as follows:




a) 2-[3-(4-Benzyl-4,7-diaza-spiro[2.5]oct-7-yl)-naphthalen-1-yl]-acetamide (280 mg, 0.73 mmol) is azeotroped twice with a 1.25 M solution of HCl in MeOH. The residue is dissolved in EtOH (10 ml). Palladium on charcoal (10%, 77 mg) is added, and the mixture is stirred

under an atmosphere of hydrogen (1 atm) at RT for 14 h and at 50 °C for 2 h. The mixture is filtered, and the filtrate is concentrated. The residue is purified by FCC (EtOAc/AcOH/H₂O 750:83.68 to 600:150:150) to yield the title compound containing 0.7 eq of AcOH. ¹H NMR (DMSO, 400 MHz) δ 0.53 (m, 4H), 1.78 (s, AcOH), 2.93 (ddd, 2H), 3.04 (s, 2H), 3.16 (ddd, 2H), 3.76 (s, 2H), 6.94 (br, 1H), 6.99 (s, 1H), 7.25 (dd, 1H), 7.26 (s, 1H), 7.35 (dd, J = 6.7 / 7.8, 1H), 7.49 (br, 1H), 7.69 (d, J = 7.8, 1H), 7.88 (d, J = 10.0, 1H); ES-MS: 296 [M+H]⁺.

b) 2-[3-(4-Benzyl-4,7-diaza-spiro[2.5]oct-7-yl)-naphthalen-1-yl]-acetamide -
[3-(4-Benzyl-4,7-diaza-spiro[2.5]oct-7-yl)-naphthalen-1-yl]-acetic acid ethyl ester (347 mg, 0.84 mmol) and formamide (126 mg, 2.80 mmol) are dissolved under an atmosphere of argon in DMF (1 ml). The solution is heated to 105 °C, and NaOMe (155 µL of a 5.4 M solution in MeOH, 45 mg, 0.84 mmol) is added dropwise during 15 minutes. After 30 minutes at 105 °C, TLC analysis indicates complete consumption of starting material. The reaction mixture is cooled to RT, diluted with water, and extracted with EtOAc. The EtOAc layers are washed twice with water. Removal of solvent and purification by FCC (EtOAc/MeOH 98:2 to 96:4 to 90:10) yielded the title compound. ¹H NMR (CDCl₃, 400 MHz) δ 0.71 (ddd, 2H), 0.89 (ddd, 2H), 3.10 (ddd, 2H), 3.16 (s, 2H), 3.31 (ddd, 2H), 3.93 (s, 2H), 3.99 (s, 2H), 5.33 (br, 1H), 5.42 (br, 1H), 7.11 (s, 1H), 7.23 (d, J = 2.0, 1H), 7.32 (m, 5H), 7.37 (dd, J = 6.7 Hz, 1H), 7.45 (dd, J = 6.7 Hz, 1H), 7.73 (d, J = 8.9 Hz, 1H), 7.85 (d, J = 8.9 Hz, 1H); ES-MS: 386 [M+H]⁺.

c) [3-(4-Benzyl-4,7-diaza-spiro[2.5]oct-7-yl)-naphthalen-1-yl]-acetic acid ethyl ester
(3-Trifluoromethanesulfonyloxy-naphthalen-1-yl)-acetic acid ethyl ester (500 mg, 1.38 mmol) is dissolved under an atmosphere of argon in dry THF (10 ml). 4-Benzyl-4,7-diaza-spiro[2.5]octane (325 mg, 1.61 mmol) is added, followed by the addition of K₃PO₄ (410 mg, 1.93 mmol), Pd₂(dba)₃ (62 mg, 0.069 mmol) and biphenyl-2-yl-di-tert-butyl-phosphane (21 mg, 0.069 mmol). The reaction mixture is heated to 80 °C. After 4 h, TLC analysis indicates complete consumption of starting materials. The reaction mixture is cooled to RT, filtered and concentrated. The residue is purified by FCC (hexanes/EtOAc 100:0 to 90:10 to 80:20 to 70:30 to 0:100) to afford the title compound. ¹H NMR (CDCl₃, 400 MHz) δ 0.69 (ddd, 2H), 0.86 (ddd, 2H), 1.24 (t, J = 7.0 Hz, 3H), 3.09 (ddd, 2H), 3.19 (s, 2H), 3.31 (ddd, 2H), 3.93 (s, 2H), 4.02 (s, 2H), 4.17 (q, J = 7.0 Hz, 2H), 7.08 (s, 1H), 7.21 (s, 1H), 7.33 (m, 6H), 7.42 (dd, J = 8.8 Hz, 1H), 7.71 (d, J = 8.8 Hz, 1H), 7.88 (d, J = 8.8 Hz, 1H); ES-MS: 415 [M+H]⁺.

d) (3-Trifluoromethanesulfonyloxy-naphthalen-1-yl)-acetic acid ethyl ester



(3-Hydroxy-naphthalen-1-yl)-acetic acid ethyl ester (1.67 g, 7.25 mmol) is dissolved in CH_2Cl_2 (20 ml) under an atmosphere of argon. Pyridine (1.17 ml, 1.15 g, 14.50 mmol) is added, and the reaction mixture is cooled to 0 °C, whereupon trifluoromethanesulfonic anhydride (1.79 ml, 3.07 g, 10.88 mmol) is added dropwise. The reaction mixture is warmed to RT, and after 1 h a RT, TLC analysis indicates complete consumption of starting material. The reaction mixture is diluted with EtOAc and washed twice with H_2O . The combined organic layers are dried over Na_2SO_4 , the solvent is removed, and the residue is purified by FCC (hexanes/EtOAc 100:0 to 97:3 to 95:5 to 93:7 to 90:10) to yield the title compound. ^1H NMR (DMSO, 400 MHz) δ 1.19 (t, J = 7.2 Hz, 3H), 4.11 (q, J = 7.2 Hz, 2H), 4.38 (s, 2H), 7.60 (d, J = 3.0 Hz, 1H), 7.70 (m, 2H), 8.03 (m, 1H), 8.12 (m, 2H); ES-MS: 362 $[\text{M}+\text{H}]^+$.

e) (3-Hydroxy-naphthalen-1-yl)-acetic acid ethyl ester

(3-Benzyloxy-naphthalen-1-yl)-acetic acid ethyl ester (2.43 g, 7.58 mmol) is dissolved in MeOH (50 ml). Palladium on charcoal (807 mg) is added, and the reaction mixture is stirred at RT under an atmosphere of hydrogen (1 atm) for 14 h. The reaction mixture is filtered. Concentration yields the pure title compound. ^1H NMR (DMSO, 400 MHz) δ 1.18 (t, J = 7.2 Hz, 3H), 4.05 (s, 2H), 4.10 (q, J = 7.2 Hz, 2H), 7.04 (d, J = 1.8 Hz, 1H), 7.06 (d, J = 1.8, 1H), 7.30 (t, J = 7.8, 1H), 7.40 (t, J = 7.8, 1H), 7.70 (d, J = 7.8, 1H), 7.80 (d, J = 7.8 Hz, 1H); ES-MS: 230 $[\text{M}+\text{H}]^+$.

f) (3-Benzyloxy-naphthalen-1-yl)-acetic acid ethyl ester

3-Benzyloxy-1-bromo-naphthalene (5.64 g, 18.01 mmol) is dissolved under an atmosphere of argon in dry DMF (100 ml). Tributylstannanyl-acetic acid ethyl ester (7.47 g, 19.81 mmol) is added, as well as [bis(tri-ortho-tolyl-phosphine)]palladium (II) dichloride (2.83 g, 3.60 mmol) and zinc(II) bromide (5.27 g, 23.41 mmol). The reaction mixture is heated to 80 °C for 3 h. The reaction mixture is diluted with EtOAc and washed twice with diluted brine (back extracted). The combined organic layers are dried over Na_2SO_4 , the solvent is removed, and the residue is purified by FCC (hexane/EtOAc 100:0 to 97.5:2.5 to 95:5 to 90:10). The resulting oil, still containing tin residues, is stirred in a 1:1 mixture of EtOAc/1N NaOH (200 ml) for 1 h. The mixture is extracted twice with EtOAc. The combined organic layers are washed twice with H_2O (back extracted), dried over Na_2SO_4 and concentrated. The residue is purified by FCC (hexane/EtOAc 100:0 to 97:3 to 95:5 to 93:7 to 92:8 to 90:10) to yield the

title compound. ^1H NMR (DMSO, 400 MHz) δ 1.18 (t, J = 7.2 Hz, 3H), 4.10 (q, J = 7.2 Hz, 2H), 4.11 (s, 2H), 5.25 (s, 2H), 7.21 (d, J = 3.0 Hz, 1H), 7.41 (m, 8H), 7.53 (d, J = 6.6 Hz, 1H), 7.84 (dd, J = 7.2 Hz, 1H); ES-MS: 320 $[\text{M}+\text{H}]^+$.

g) 3-Benzyloxy-1-bromo-naphthalene

4-Bromo-naphthalen-2-ol (5.0 g, 22.41 mmol) is dissolved in dry DMF (50 ml) under an atmosphere of argon. Sodium hydride (986 mg of a 60% suspension in mineral oil, 592 mg, 24.65 mmol) is added and the mixture is stirred at 50 °C for 1 h. After re-cooling to RT, benzyl bromide (3.46 ml, 4.98 g, 29.14 mmol) and tetrabutyl ammoniumiodide (828 mg, 2.24 mmol) are added. After 16 h at RT, the reaction mixture is diluted with EtOAc. The solution is washed twice with semi-concentrated brine (back extracted). The combined organic layers are dried over Na_2SO_4 , the solvent is removed, and the residue is purified by FCC (hexane/EtOAc 100:0 to 95:5 to 90:10) to yield the title compound. ^1H NMR (CDCl_3 , 400 MHz) δ 5.22 (s, 2H), 7.25 (d, J = 1.5 Hz, 1H), 7.45 (m, 7H), 7.64 (d, J = 2.4, 1H), 7.75 (d, J = 7.8, 1H), 8.17 (d, J = 7.8, 1H); ES-MS: 312 $[\text{M}+\text{H}]^+$.

By following procedure of example 11, the compounds of formula I wherein R is a residue of formula (b), as indicated in Table 2 may be obtained.

TABLE 2

Example	R ₄	R _a	M.S. Data
12	3- <i>R</i> -methyl-piperazin-1-yl	CH ₃	MH ⁺ 452
13	-(4,7-diaza-spiro[2,5]oct-7-yl)	CH ₃	MH ⁺ 464
14	-(4,7-diaza-spiro[2,5]oct-7-yl)	H	MH ⁺ 450
15	3- <i>R</i> -methyl-piperazin-1-yl	H	MH ⁺ 438
16	3- <i>S</i> -methyl-piperazin-1-yl	CH ₃	MH ⁺ 452
17	3- <i>S</i> -methyl-piperazin-1-yl	H	MH ⁺ 438
18	4-methyl-3- <i>S</i> -methyl-piperazin-1-yl	CH ₃	MH ⁺ 466
19	4-methyl-3- <i>S</i> -methyl-piperazin-1-yl	H	MH ⁺ 452

By following the procedure as disclosed in Example 56 in PCT/EPO1/12785, but using the appropriate starting materials the compounds of formula I wherein R is a residue of formula (c), as indicated in Table 3 below may be obtained.

TABLE 3


Example	R ₁₄	R ₁₅	R ₁₆	R _a	M.S. Data
20	-(4-methyl-piperazin-1-yl)	CH ₃	Cl	H	MH ⁺ 437
21	-(4-methyl-piperazin-1-yl)	H	Br	H	MH ⁺ 467, 469
22	-(4-methyl-piperazin-1-yl)	CH ₃	Br	H	MH ⁺ 481, 483
23	-(4-methyl-piperazin-1-yl)	H	Br	CH ₃	MH ⁺ 481, 483
24	-(4-methyl-piperazin-1-yl)	H	CF ₃	H	MH ⁺ 457
25	-(4-methyl-piperazin-1-yl)	H	CF ₃	CH ₃	MH ⁺ 471
26	3- <i>R</i> -methyl-piperazin-1-yl	CH ₃	Cl	H	MH ⁺ 437
27	-(4,7-diaza-spiro[2,5]oct-7-yl)	CH ₃	Cl	H	MH ⁺ 449
28	1-piperazinyl	CH ₃	Cl	H	MH ⁺ 423
29	3- <i>R</i> -methyl-piperazin-1-yl	CH ₃	Cl	H	MH ⁺ 437
30	4-methyl-3- <i>R</i> -methyl-piperazin-yl	CH ₃	Cl	H	MH ⁺ 451

By following the procedure as disclosed in Example 163 in PCT/EPO1/12785, but using the appropriate starting material the compounds of formula I wherein R is a residue of formula (d), as indicated in Table 4 below, may be obtained.

TABLE 4


Example	R ₈	R _a	M.S. Data
31	3- <i>S</i> -methyl-piperazin-1-yl	CH ₃	MH ⁺ 452
32	3- <i>R</i> -methyl-piperazin-1-yl	H	MH ⁺ 438
33	3- <i>R</i> -methyl-piperazin-1-yl	CH ₃	MH ⁺ 452
34	4-benzyl-1-piperazinyl	H	MH ⁺ 514
35	4-benzyl-1-piperazinyl	CH ₃	MH ⁺ 528
36	1-piperazinyl	CH ₃	MH ⁺ 438
37	1-piperazinyl	H	MH ⁺ 424

Example 38: 3-[3-(4,7-Diaza-spiro[2.5]oct-7-yl)-isoquinolin-1-yl]-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione



2-[3-(4,7-Diaza-spiro[2.5]oct-7-yl)-isoquinolin-1-yl]-acetamide (160 mg, 0.38 mmol) and (1-methyl-1H-indol-3-yl)-oxo-acetic acid methyl ester (125 mg, 0.57 mmol) are azeotroped twice with dry THF. Dry THF (4 ml) is then added, and under an atmosphere of argon KOtBu (1.0 M in THF, 1.9 ml, 1.9 mmol) is added dropwise during 20 minutes. After an additional 5 min, TLC analysis indicates complete conversion of starting materials. The reaction mixture is diluted with H₂O and extracted twice with EtOAc. The combined organic layers are washed twice with saturated aq NH₄Cl solution (back extracted), dried over Na₂SO₄ and concentrated. Purification by FCC (CH₂Cl₂/MeOH 100:0 to 98:2 to 96:4 to 94:6 to 92:8 to 90:10) yields the title compound, which is converted to its bis-trifluoroacetate salt by concentration of a CH₂Cl₂/TFA solution (128 mg, 48%). ¹H NMR (DMSO, 400 MHz) δ 0.92 (br, 4 H), 3.18 – 3.24 (br m, 2H), 3.18 – 3.24 (br m, 2H), 3.61 – 3.84 (br m, 2H), 3.78 (br s, 2H), 3.88 (s, 3H), 5.98 (d, J = 7.9 Hz, 1H), 6.54 (t, J = 7.5 Hz, 1H), 7.04 (t, J = 8.0 Hz, 1H), 7.14 (t, J = 7.6 Hz, 1H), 7.28 (s, 1H), 7.41 (d, J = 8.2 Hz, 1H), 7.51 (t, J = 7.3 Hz, 1H), 7.70 (d, J = 8.72 Hz, 2H), 8.23 (s, 1H), 9.02 – 9.12 (br, 2H), 11.21 (s, 1H); ES-MS: 464 [M+H]⁺.

2-[3-(4,7-Diaza-spiro[2.5]oct-7-yl)-isoquinolin-1-yl]-acetamide used as starting material may be prepared as follows:



a) 2-[3-(4-Benzyl)-4,7-diaza-spiro[2.5]oct-7-yl]-isoquinolin-1-yl]-acetamide (490 mg, 1.27 mmol) is dissolved in absolute MeOH (5 ml). Palladium on charcoal (140 mg) is added, as well as ammonium formate (200 mg, 3.17 mmol). After refluxing for 1 h (T = 75 °C), an additional charge of ammonium formate (200 mg, 3.17 mmol) is added. 1 h later, TLC analysis indicates complete conversion of the starting material. After filtration and concentration, the residue is taken up in CH₂Cl₂ and washed with water (pH 10 by addition of 2 N NaOH). The organic layer is dried over Na₂SO₄ and the solvent is removed. Purification by FCC (EtOAc/AcOH/H₂O 750:83:68 to 700:110:90 to 650:130:120 to 600:150:150) affords

the title compound as its bis-acetate salt. ^1H NMR (DMSO, 400 MHz) δ 0.46 – 0.52 (m, 4H), 2.88 (t, J = 5.5, 2H), 3.35 (s, 2H), 3.49 (t, J = 5.5, 2H), 3.94 (s, 2H), 6.77 (s, 1H), 7.00 (br s, 1H), 7.18 – 7.25 (m, 1H), 7.45 – 7.56 (m, 2H), 7.60 – 7.65 (m, 1H), 7.95 (d, J = 9.9, 1H). ES-MS: 297 $[\text{M}+\text{H}]^+$.

b) 2-[3-(4-Benzyl-4,7-diaza-spiro[2.5]oct-7-yl)-isoquinolin-1-yl]-acetamide
[3-(4-Benzyl-4,7-diaza-spiro[2.5]oct-7-yl)-isoquinolin-1-yl]-acetic acid ethyl ester (700 mg, 1.68 mmol) is dissolved in dry DMF under an atmosphere of argon. Formamide (224 μL , 254 mg, 5.64 mmol) is added, and the reaction mixture is heated to 105 °C. At this temperature, NaOMe (312 μL of a 5.4 M solution in MeOH, 91 mg, 1.68 mmol) is added dropwise during 20 minutes. After 30 minutes at 105 °C, TLC analysis indicates complete conversion of starting material. Cooling the reaction mixture to RT is followed by addition of water and extraction with EtOAc. The organic layers are washed with H_2O (twice), dried over Na_2SO_4 and concentrated. The residue is purified by FCC (hexane/EtOAc 1:1 to 1:3 to 0:100 to EtOAc/MeOH 98:2) to afford the title compound. ^1H NMR (DMSO, 400 MHz) δ 0.68 – 0.70 (m, 2H), 0.82 – 0.88 (m, 2H), 3.08 (t, J = 4.4, 2H), 3.45 (s, 2H), 3.58 (t, J = 4.4, 2H), 3.96 (s, 2H), 4.27 (s, 2H), 5.3 – 5.5 (br, 1H), 6.55 – 6.7 (br, 1H), 6.72 (s, 1H), 7.26 – 7.36 (m, 6H), 7.51 (t, J = 8.8, 1H), 7.60 d, J = 9.9, 1H), 8.02 (d, J = 9.9, 1H); ES-MS: 387 $[\text{M}+\text{H}]^+$.

c) [3-(4-Benzyl-4,7-diaza-spiro[2.5]oct-7-yl)-isoquinolin-1-yl]-acetic acid ethyl ester
(3-Chloro-isoquinolin-1-yl)-acetic acid ethyl ester (2.50 g, 10.01 mmol), 4-benzyl-4,7-diaza-spiro[2.5]octane (2.23 g, 11.01 mmol), NaOtBu (1.06 g, 11.01 mmol), BINAP (249 mg, 0.40 mmol) and Pd(II)-acetate (180 mg, 0.80 mmol) are mixed under argon. After addition of degassed, dry dioxane (36 ml), the suspension is heated to 85 °C. After 25 minutes at 85 °C, HPLC analysis indicates a conversion of 71%. The mixture is cooled to RT, diluted with EtOAc, and washed with H_2O and sat. aq. NH_4Cl (back extracted). The combined organic layers are dried over Na_2SO_4 , the solvent is removed and the residue is purified by FCC (hexane/EtOAc 100:0 to 96:4 to 93:7 to 90:10 to 85:15) to afford the title compound. ^1H NMR (DMSO, 400 MHz) δ 0.58 – 0.61 (m, 2H), 0.70 – 0.73 (m, 2H), 1.18 (t, J = 8.8, 3H), 2.98 (t, J = 5.5, 2H), 3.39 (s, 2H), 3.49 (t, J = 5.5, 2H), 3.86 (s, 2H), 4.12 (s, 2H), 4.12 (q, J = 8.8, 2H), 5.59 (s, 1H), 7.14 – 7.19 (m, 6H), 7.39 (t, J = 8.8, 1H), 7.51 (d, J = 9.9, 1H), 7.78 (d, J = 9.9, 1H); ES-MS: 417 $[\text{M}+\text{H}]^+$.

d) (3-Chloro-isoquinolin-1-yl)-acetic acid ethyl ester
1,1,1,3,3-Hexamethyl-disilazane (27.4 ml, 20.37 g, 126.2 mmol) is dissolved in dry toluene (150 ml). After cooling to –78 °C, $n\text{-BuLi}$ (79 ml of a 1.6 M solution in hexanes, 126.2 mmol) is slowly added during 20 minutes. The white suspension is stirred at –78 °C for 15 minutes

and at RT for 15 minutes, after which time a clear bright yellow solution is obtained. This solution is cannulated into a second two-necked flask, containing $\text{Pd}_2(\text{dba})_3$ (1.39 g, 1.51 mmol) and (2'-dicyclohexylphosphanyl-biphenyl-2-yl)-dimethyl-amine (1.25 g, 3.18 mmol). After stirring at RT for 10 minutes, the clear dark red solution is cooled to -10°C . Acetic acid tert-butyl ester (15.7 ml, 13.5 g, 116.1 mmol) is added during 5 minutes. After 10 minutes at -10°C , 1,3-dichloro-isoquinoline (10.0 g, 50.49 mmol) is added in one portion. The dark red solution is allowed to warm to RT. After 30 minutes at RT, TLC analysis indicates complete conversion of the starting material. The reaction mixture is filtered through a 2-cm pad of silica, which is rinsed with EtOAc/MeOH 98:2. After concentration, the residue is purified by FCC (toluene/ CH_2Cl_2 2:1 to toluene/EtOAc 100:0 to 99:1 to 98:2 to 97:3 to 96:4 to 94:6 to 90:10) to afford (3-Chloro-isoquinolin-1-yl)-acetic acid tert.-butyl ester. This compound is dissolved in a saturated ethanolic solution of HCl (200 ml) and refluxed for 15 minutes. Concentration afforded the title compound. ^1H NMR (DMSO, 400 MHz) δ 1.17 (t, $J = 8.8$, 3H), 4.11 (q, $J = 8.8$, 2H), 4.28 (s, 2H), 7.51 – 7.57 (m, 1H), 7.61 (s, 1H), 7.61 – 7.66 (m, 1H), 7.72 (d, $J = 8.8$, 1H), 7.98 (d, $J = 8.8$, 1H); ES-MS: 250 $[\text{M}+\text{H}]^+$.

By following the procedure of Example 38 but using the appropriate starting materials, the compounds of formula I wherein R is residue of formula (e), as indicated in Table 5 below, may be obtained.

TABLE 5

Example	R _b	R _a	M.S. Data
39	-(4,7-diaza-spiro[2,5]oct-7-yl)	CH ₃	MH ⁺ 465
40	3-ethyl-piperazin-1-yl	CH ₃	MH ⁺ 467
41	-(4,7-diaza-spiro[2,5]oct-7-yl)	H	MH ⁺ 451
42	3-ethyl-1-piperaziny	H	MH ⁺ 453
43	3- <i>R</i> -methyl-piperazin-1-yl	CH ₃	MH ⁺ 453
44	3- <i>R</i> -methyl-piperazin-1-yl	H	MH ⁺ 439
45	3- <i>S</i> -methyl-piperazin-1-yl	CH ₃	MH ⁺ 453
46	3- <i>S</i> -methyl-piperazin-1-yl	H	MH ⁺ 439
47	4-methyl-3- <i>S</i> -methyl-piperazin-1-yl	CH ₃	MH ⁺ 467
48	4-methyl-3- <i>S</i> -methyl-piperazin-1-yl	H	MH ⁺ 453

The compounds of formula I in free form or in pharmaceutically acceptable salt form exhibit valuable pharmacological properties, e.g. inhibiting Protein Kinase C (PKC), e.g. PKC isoforms like α , β , δ , ϵ , η or θ activity, inhibiting T-cell activation and proliferation, e.g. by inhibiting production by T-cells or cytokines, e.g. IL-2, by inhibiting the proliferative response of T-cells to cytokines, e.g. IL-2, e.g. as indicated in in vitro and in vivo tests and are therefore indicated for therapy.

A. In vitro

1. Protein Kinase C assay

The compounds of formula I are tested for their activity on different PKC isoforms according to a published method (D. Geiges et al. Biochem. Pharmacol. 1997;53:865-875) The assay is performed in a 96-well polypropylene microtiterplate (Costar 3794) that has been previously siliconized with Sigmacote (Sigma SL-2). The reaction mixture (50 μ l) contains 10 μ l of the relevant PKC isozyme together with 25 μ l of the test compound and 15 μ l of a mix solution that contains 200 μ g/ml protamine sulfate, 10 mM $\text{Mg}(\text{NO}_3)_2$, 10 μ M ATP (Boehringer 519987) and 3750 Bq of ^{33}P -ATP (Hartmann Analytic SFC301, 110TBq/mmol) in 20 mM Tris-buffer pH 7.4 + 0.1% BSA. Incubation is performed for 15 min at 32°C in a microtiterplate shaking incubator (Biolabo Scientific Instruments). Reaction is stopped by adding 10 μ l of 0.5 M Na_2EDTA , pH 7.4. 50 μ l of mixture are pipetted onto a pre-wetted phosphocellulose paper (Whatmann 3698-915) under gentle pressure. Non-incorporated ATP is washed away with 100 μ l bi-dist H_2O . The paper is washed twice in 0.5% H_3PO_4 for 15 min followed by 5 min in EtOH. Thereafter the paper is dried and placed in an omnifilter (Packard 6005219), and overlayed with 10 μ l/well of Microscint-O (Packard 6013611) before counting in a Topcount radioactivity counter (Packard). IC_{50} measurement is performed on a routine basis by incubating a serial dilution of inhibitor at concentrations ranging between 1-1000 μ M according to the method described above. IC_{50} value are calculated from the graph by sigmoidal curve fitting.

2. Protein Kinase C θ Assay

Human recombinant PKC θ is used under the assay conditions as described above. In this assay, compounds of formula I inhibit PKC θ with an $\text{IC}_{50} \leq 1$ μ M. Compound of Example 20 inhibits PKC θ in this assay with an IC_{50} 4.5 nM.

3. Protein Kinase C α Assay

Human recombinant PKC α was obtained from Oxford Biomedical Research and is used under the assay conditions as described under Section A.1 above. In this assay, compounds of formula I inhibit PKC θ with an $IC_{50} \leq 1 \mu M$. Compound of Example 20 inhibits PKC α in this assay with an IC_{50} of 4.3 nM.

4. Protein Kinase C β 1 Assay

Human recombinant PKC β 1 was obtained from Oxford Biomedical Research and is used under the assay conditions as described under Section A.1 above. In this assay, compounds of formula I inhibit PKC θ with an $IC_{50} \leq 1 \mu M$. Compound of Example 20 inhibits PKC β 1 in this assay with an IC_{50} of 22 nM.

5. Protein Kinase C δ Assay

Human recombinant PKC δ was obtained from Oxford Biomedical Research and is used under the assay conditions as described under Section A.1 above. In this assay, compounds of formula I inhibit PKC θ with an $IC_{50} \leq 1 \mu M$. Compound of Example 20 inhibits PKC δ in this assay with an IC_{50} of 21nM.

6. Protein Kinase C ϵ Assay

Human recombinant PKC ϵ was obtained from Oxford Biomedical Research and is used under the assay conditions as described under Section A.1 above. In this assay, compounds of formula I inhibit PKC θ with an $IC_{50} \leq 1 \mu M$. Compound of Example 20 inhibits PKC ϵ in this assay with an IC_{50} of 19 nM.

7. Protein Kinase C η Assay

Human recombinant PKC η was obtained from PanVera and is used under the assay conditions as described under Section A.1 above. In this assay, compounds of formula I inhibit PKC θ with an $IC_{50} \leq 1 \mu M$. Compound of Example 20 inhibits PKC η in this assay with an IC_{50} of 26 nM.

8. CD28 costimulation assay

The assay is performed with Jurkat cells transfected with a human interleukin-2 promoter/reporter gene construct as described by Baumann G et al. in Transplant.Proc. 1992;24:43-8, the β -galactosidase reporter gene being replaced by the luciferase gene (de Wet J., et al., Mol. Cell Biol. 1987, 7(2), 725-737). Cells are stimulated by solid phase-coupled antibodies or phorbol myristate acetate (PMA) and the Ca^{++} ionophore Ionomycin as follows. For antibody-mediated stimulation Microlite.TM1 microtiter plates (Dynatech) are coated with 3 $\mu g/ml$ goat anti-mouse IgG Fc antibodies (Jackson) in 55 μl phosphate-

buffered saline (PBS) per well for three hours at RT. Plates are blocked after removing the antibodies by incubation with 2% bovine serum albumin (BSA) in PBS (300 μ l per well) for 2 hours at RT. After washing three times with 300 μ l PBS per well, 10 ng/ml anti-T cell receptor antibodies (WT31, Becton & Dickinson) and 300 ng/ml anti-CD28 antibodies (15E8) in 50 μ l 2% BSA/PBS are added as stimulating antibodies and incubated overnight at 4°C. Finally the plates are washed three times with 300 μ l PBS per well. Seven three-fold serial dilutions of test compounds in duplicates in assay medium (RPMI 1640/10% fetal calf serum (FCS) containing 50 μ M 2-mercaptoethanol, 100 units/ml penicillin and 100 μ g/ml streptomycin) are prepared in separate plates, mixed with transfected Jurkat cells (clone K22 290_H23) and incubated for 30 minutes at 37°C in 5% CO₂. 100 μ l of this mixture containing 1×10^5 cells are then transferred to the antibody-coated assay plates. In parallel 100 μ l are incubated with 40 ng/ml PMA and 2 μ M ionomycin. After incubation for 5.5 hours at 37°C in 5% CO₂, the level of luciferase is determined by bioluminescence measurement. The plates are centrifuged for 10 min at 500 g and the supernatant is removed by flicking. Lysis buffer containing 25 mM Tris-phosphate, pH 7.8, 2 mM DTT, 2 mM 1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid, 10 % (v/v) glycerol and 1 % (v/v) Triton X-100 is added (20 μ l per well). The plates are incubated at RT for 10 minutes under constant shaking. Luciferase activity is assessed with a bioluminescence reader (Labsystem, Helsinki, Finland) after automatic addition of 50 μ l per well luciferase reaction buffer containing 20 mM Tricine, 1.07 mM (MgCO₃)₄Mg(OH)₂·5H₂O, 2.67 mM MgSO₄, 0.1 mM EDTA, 33.3 mM DTT, 270 μ M coenzyme A, 470 μ M luciferin (Chemie Brunschwig AG), 530 μ M ATP, pH 7.8. Lag time is 0.5 seconds, total measuring time is 1 or 2 seconds. Low control values are light units from anti-T cell receptor- or PMA-stimulated cells, high controls are from anti-T cell receptor/anti-CD28- or PMA/ionomycin-stimulated cells without any test sample. Low controls are subtracted from all values. The inhibition obtained in the presence of a test compound is calculated as percent inhibition of the high control. The concentration of test compounds resulting in 50% inhibition (IC₅₀) is determined from the dose-response curves. In this assay, compounds of formula I inhibit anti-T cell receptor/anti-CD28 and PMA/ionomycin stimulated Jurkat cells with an IC₅₀ \leq 1 μ M. Compound of Example 20 has an IC₅₀ of 20 nM in this assay.

9. Allogeneic Mixed Lymphocyte Reaction (MLR)

The two-way MLR is performed according to standard procedures (J. Immunol. Methods, 1973, 2, 279 and Meo T. et al., Immunological Methods, New York, Academic Press, 1979,

227-39). Briefly, spleen cells from CBA and BALB/c mice (1.6×10^5 cells from each strain per well in flat bottom tissue culture microtiter plates, 3.2×10^5 in total) are incubated in RPMI medium containing 10% FCS, 100 U/ml penicillin, 100 µg/ml streptomycin (Gibco BRL, Basel, Switzerland), 50 µM 2-mercaptoethanol (Fluka, Buchs, Switzerland) and serially diluted compounds. Seven three-fold dilution steps in duplicates per test compound are performed. After four days of incubation 1 µCi ^3H -thymidine is added. Cells are harvested after an additional five-hour incubation period, and incorporated ^3H -thymidine is determined according to standard procedures. Background values (low control) of the MLR are the proliferation of BALB/c cells alone. Low controls are subtracted from all values. High controls without any sample are taken as 100% proliferation. Percent inhibition by the samples is calculated, and the concentrations required for 50% inhibition (IC_{50} values) are determined. In this assay, Compound of Example 20 has an IC_{50} of 28 nM.

10. Inhibition of GSK-3 β

The GSK-3 β binding assay is performed in 50µl reactions in 96 well polypropylene plate, each reaction containing 20mM magnesium chloride, 40 µM ATP, 2mM DTT, 88.5µM biotinylated and phosphorylated CREB-peptide substrate (biotin-KRREILSRRPS(PO_4)YR-OH ; Q. M. Wang et al., J. Biol. Chem. 269, 14566-14574, 1994), [γ - ^{33}P]ATP (1µCi) and 2µl of the compound to be tested in DMSO(various concentrations). 15µl of GSK-3 β (various concentrations) is added and the mixture is incubated at 30°C for 1 hour. The reaction is stopped by transferring 25 µl of the mixture to a phosphocellulose plate containing 130µl of 1.85% phosphoric acid. The free radionucleotides in the membrane are washed off under vacuum with 1.85% phosphoric acid (5 times). After the last wash, the plate is transferred to an adaptor plate and 50µl of scintillation cocktail (Microscint-20, Packard, cat. #20-133) is added to each well and the amount of radioactivity is counted in a top counter. Compounds of formula I are active in this assay.

B. In vivo

Rat Heart transplantation

The strain combination used: Male Lewis (RT^1 haplotype) and BN (RT^1 haplotype). The animals are anaesthetised using inhalational isofluorane. Following heparinisation of the donor rat through the abdominal inferior vena cava with simultaneous exsanguination via the aorta, the chest is opened and the heart rapidly cooled. The aorta is ligated and divided distal to the first branch and the brachiocephalic trunk is divided at the first bifurcation. The left pulmonary artery is ligated and divided and the right side divided but left open. All other

vessels are dissected free, ligated and divided and the donor heart is removed into iced saline.

The recipient is prepared by dissection and cross-clamping of the infra-renal abdominal aorta and vena cava. The graft is implanted with end-to-side anastomoses, using 10/0 monofilament suture, between the donor brachiocephalic trunk and the recipient aorta and the donor right pulmonary artery to the recipient vena cava. The clamps are removed, the graft tethered retroabdominally, the abdominal contents washed with warm saline and the animal is closed and allowed to recover under a heating lamp. Graft survival is monitored by daily palpation of the beating donor heart through the abdominal wall. Rejection is considered to be complete when heart beat stops. Increases of graft survival are obtained in animals treated with a compound of formula I administered orally at a daily dose of 1 to 30 mg/kg.

Graft v. Host Model

Spleen cells (2×10^7) from Wistar/F rats are injected subcutaneously into the right hind footpad of (Wistar/F x Fischer 344) F_1 hybrid rats. The left footpad is left untreated. The animals are treated with the test compounds on 4 consecutive days (0-3). The popliteal lymph nodes are removed on day 7, and the weight differences between two corresponding lymph nodes are determined. The results are expressed as the inhibition of lymph node enlargement (given in percent) comparing the lymph node weight differences in the experimental groups to the weight difference between the corresponding lymph nodes from a group of animals left untreated with a test compound. In this assay, an inhibition of 100% is obtained with compound of Example 20 when administered at a dose of 30mg/kg/day bid.

The compounds of formula I are, therefore, useful in the treatment and/or prevention of diseases or disorders mediated by T lymphocytes and/or PKC, e.g. acute or chronic rejection of organ or tissue allo- or xenografts, graft versus host diseases, atherosclerosis, vascular occlusion due to vascular injury such as angioplasty, restenosis, obesity, syndrome X, impaired glucose tolerance, polycystic ovary syndrome, hypertension, heart failure, chronic obstructive pulmonary disease, CNS diseases such as Alzheimer disease or amyotrophic lateral sclerosis, cancer, infectious diseases such as AIDS, septic shock or adult respiratory distress syndrome, ischemia/reperfusion injury e.g. myocardial infarction, stroke, gut ischemia, renal failure or hemorrhage shock, or traumatic shock, e.g. traumatic brain injury. The compounds of formula I are also useful in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders or autoimmune diseases e.g.

rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, respiratory diseases such as asthma or inflammatory lung injury, inflammatory liver injury, inflammatory glomerular injury, cutaneous manifestations of immunologically-mediated disorders or illnesses, inflammatory and hyperproliferative skin diseases (such as psoriasis, atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis and further eczematous dermatitises, seborrhoeic dermatitis), inflammatory eye diseases, e.g. Sjogren's syndrome, keratoconjunctivitis or uveitis, inflammatory bowel disease, Crohn's disease or ulcerative colitis. For the above uses the required dosage will of course vary depending on the mode of administration, the particular condition to be treated and the effect desired. In general, satisfactory results are indicated to be obtained systemically at daily dosages of from about 0.1 to about 100 mg/kg body weight. An indicated daily dosage in the larger mammal, e.g. humans, is in the range from about 0.5 mg to about 2000 mg, conveniently administered, for example, in divided doses up to four times a day or in retard form.

The compounds of formula I may be administered by any conventional route, in particular enterally, e.g. orally, e.g. in the form of tablets or capsules, or parenterally, e.g. in the form of injectable solutions or suspensions, topically, e.g. in the form of lotions, gels, ointments or creams, or in a nasal or a suppository form. Pharmaceutical compositions comprising a compound of formula I in free form or in pharmaceutically acceptable salt form in association with at least one pharmaceutical acceptable carrier or diluent may be manufactured in conventional manner by mixing with a pharmaceutically acceptable carrier or diluent. Unit dosage forms for oral administration contain, for example, from about 0.1 mg to about 500 mg of active substance.

Topical administration is e.g. to the skin. A further form of topical administration is to the eye.

The compounds of formula I may be administered in free form or in pharmaceutically acceptable salt form e.g. as indicated above. Such salts may be prepared in conventional manner and exhibit the same order of activity as the free compounds.

In accordance with the foregoing the present invention further provides:

- 1.1 A method for preventing or treating disorders or diseases mediated by T lymphocytes and/or PKC or GSK-3 β , e.g. such as indicated above, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof;

- 1.2 A method for preventing or treating acute or chronic transplant rejection or T-cell mediated inflammatory or autoimmune diseases, e.g. as indicated above, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof;
2. A compound of formula I, in free form or in a pharmaceutically acceptable salt form for use as a pharmaceutical, e.g. in any of the methods as indicated under 1.1 and 1.2 above.
3. A pharmaceutical composition, e.g. for use in any of the methods as in 1.1 and 1.2 above comprising a compound of formula I in free form or pharmaceutically acceptable salt form in association with a pharmaceutically acceptable diluent or carrier therefor.
4. A compound of formula I or a pharmaceutically acceptable salt thereof for use in the preparation of a pharmaceutical composition for use in any of the method as in 1.1 and 1.2 above.

Compounds of formula I may be administered as the sole active ingredient or together with other drugs in immunomodulating regimens or other anti-inflammatory agents e.g. for the treatment or prevention of allo- or xenograft acute or chronic rejection or inflammatory or autoimmune disorders. For example, they may be used in combination with cyclosporines, or ascomycines or their immunosuppressive analogs or derivatives, e.g. cyclosporin A, cyclosporin G, FK-506, ABT-281, ASM 981; an mTOR inhibitor, e.g. rapamycin, 40-O-(2-hydroxy)ethyl-rapamycin etc.; corticosteroids; cyclophosphamide; azathioprene; methotrexate; an accelerating lymphocyte homing agent, e.g. FTY 720; leflunomide or analogs thereof; mizoribine; mycophenolic acid; mycophenolate mofetil; 15-deoxyspergualine or analogs thereof; immunosuppressive monoclonal antibodies, e.g., monoclonal antibodies to leukocyte receptors, e.g., MHC, CD2, CD3, CD4, CD 11a/CD18, CD7, CD25, CD 27, B7, CD40, CD45, CD58, CD 137, ICOS, CD150 (SLAM), OX40, 4-1BB or their ligands, e.g. CD154; or other immunomodulatory compounds, e.g. a recombinant binding molecule having at least a portion of the extracellular domain of CTLA4 or a mutant thereof, e.g. an at least extracellular portion of CTLA4 or a mutant thereof joined to a non-CTLA4 protein sequence, e.g. CTLA4Ig (for ex. designated ATCC 68629) or a mutant thereof, e.g. LEA29Y, or other adhesion molecule inhibitors, e.g. mAbs or low molecular weight inhibitors including LFA-1 antagonists, Selectin antagonists and VLA-4 antagonists. Compounds of formula I may also be administered together with an

antiproliferative drug, e.g. a chemotherapeutic drug, e.g. in cancer treatment, or with an anti-diabetic drug, an insulin secretagogue, insulin secretion enhancer or an insulin sensitizer, in diabetes therapy,


In accordance with the foregoing the present invention provides in a yet further aspect:

5. A method as defined above comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective amount of an inhibitor of GSK-3 β , PKC or of T-cell activation and proliferation, e.g. a compound of formula I in free form or in pharmaceutically acceptable salt form, and a second drug substance, said second drug substance being an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic drug, e.g. as indicated above.
6. A therapeutic combination, e.g. a kit, comprising a) an inhibitor of GSK-3 β , PKC or of T-cell activation and proliferation, e.g. a compound of formula I in free form or in pharmaceutically acceptable salt form, and b) at least one second agent selected from an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative and anti-diabetic drug. Component a) and component b) may be used concomitantly or in sequence. The kit may comprise instructions for its administration.

Where an inhibitor of GSK-3 β , PKC or of T-cell activation and proliferation, e.g. a compound of formula I, is administered in conjunction with other immunosuppressive/immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic therapy, e.g. for preventing or treating acute or chronic graft rejection or inflammatory or autoimmune disorders as hereinabove specified, dosages of the co-administered immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic compound will of course vary depending on the type of co-drug employed, e.g. whether it is a steroid or a cyclosporine, on the specific drug employed, on the condition being treated and so forth.

CLAIM

1. A compound of formula I




wherein

R_a is H, CH₃ or isopropyl,

R_b is H; halogen; CF₃; C₁₋₆alkoxy; C₁₋₆alkyl; or C₃₋₇cycloalkyl; and either

- I. R is a radical of formula (a)



(a)


wherein

R₁ is piperazin-1-yl optionally substituted by CH₃ in position 3 or 4,

R₂ is H; CH₃; or CF₃; and

R₃ is Cl; Br; CF₃; or CH₃; or


- II. R is a radical of formula (b)



(b)

wherein R₄ is piperazin-1-yl, 3-methyl-piperazin-1-yl or 4,7-diaza-spiro [2,5] oct-7-yl; or

- III. R is a residue of formula (c)



(c)


wherein

R_{14} is piperazin-1-yl optionally substituted by CH_3 in position 3 or 4, or 4,7-diaza-spiro [2,5] oct-7-yl;

R_{15} is H; CH_3 ; or CF_3 ; and

R_{16} is Cl; Br; CF_3 ; or CH_3 ; each of R_{15} and R_{16} being other than CH_3 when R_b is H; or


IV. R is a radical of formula (d)



(d)

wherein R_8 is piperazin-1-yl, 3-methyl-piperazin-1-yl or 4-benzyl-piperazin-1-yl; or

V. R is a radical of formula (e)



(e)

wherein R_9 is 4,7-diaza-spiro [2,5] oct-7-yl; or piperazin-1-yl substituted in position

3 by methyl or ethyl,

or a salt thereof,

its preparation, its use as a pharmaceutical, and a pharmaceutical composition containing such a compound, substantially as hereinbefore disclosed or defined.

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**